Scientific presentations reveal how Seer’s Proteograph Product Suite is a critical component of multi-omic translational studies and enables profiling of protein isoform-specific biomarkersREDWOOD CITY, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation at the upcoming American Society of Human Genetics (ASHG) 2025 Annual Meeting, taking place October 14-18 in Boston. As human genetics ...

SEATTLE, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2025 before market open on Tuesday, October 28, 2025. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast w ...

Core Viewpoint - Biotech stocks are experiencing renewed momentum, with small-cap companies like Nautilus Biotechnology, PepGen, Lixte, RenovoRx, Genelux, and VolitionRx attracting investor interest through various catalysts such as insider buying, strategic partnerships, and clinical trial progress Group 1: Nautilus Biotechnology (NAUT) - Nautilus Biotechnology's stock surged 5.52% during regular trading, closing at $0.7070, and rose an additional 7.5% in after-hours trading to $0.76, with trading volume nearly double its average at 647,399 shares [2] - Recent insider buying by CEO Sujal M. Patel, who purchased 83,500 shares on September 8 and 116,500 shares on September 5, totaling over $135,000, indicates strong leadership confidence [3] - The company reported a narrower loss of $0.12 per share in Q2 2025, with an 18% drop in operating expenses, and has $179.5 million in cash, providing a financial runway through 2027 [4] Group 2: PepGen Inc. (PEPG) - PepGen's stock rebounded 7.14% in after-hours trading to $1.50 after a regular session close of $1.40, with trading volume more than double its average at 638,576 shares [4] - The company completed dosing for its 15 mg/kg arm of the FREEDOM trial, with topline data expected in early Q4 2025, following a strategic narrowing of its pipeline [5] Group 3: Lixte Biotechnology Holdings Inc. (LIXT) - Lixte's stock rose 5.85% in after-hours trading to $5.25 after closing at $4.96, with a trading volume of 503,604 shares, notable given recent volatility [5] - The company announced a $2.6 million purchase of Bitcoin and Ethereum to diversify its treasury holdings, reflecting a strategic shift in financial strategy [6] Group 4: RenovoRx Inc. (RNXT) - RenovoRx shares increased 4.22% in after-hours trading to $1.2194 after a regular session close of $1.17, with trading volume significantly above its average at 886,119 shares [6] - The company received a positive recommendation to continue its Phase III TIGeR-PaC trial for pancreatic cancer, reinforcing confidence in its lead therapy platform [7] Group 5: Genelux Corp. (GNLX) - Genelux's stock rose 4.11% in after-hours trading to $3.80 after closing at $3.65, with trading volume relatively light at 60,339 shares [8] - The recent activity follows Genelux's participation in the H.C. Wainwright Global Investment Conference [9] Group 6: VolitionRx Ltd. (VNRX) - VolitionRx's stock increased 4.27% in after-hours trading to $0.6474 after closing at $0.6209, with trading volume slightly below its average at 183,777 shares [10] - The company announced a Research License and Exclusive Commercial Option Rights Agreement with Werfen's Immunoassay Technology Center, focusing on advancing its Nu.Q NETs assay for Antiphospholipid Syndrome [10]

Summary of Sera Prognostics Conference Call Company Overview - **Company**: Sera Prognostics - **Industry**: Healthcare, specifically focused on pregnancy and preterm birth risk assessment - **Product**: PreTRM Test, a clinically validated test for screening risks of spontaneous premature birth [2][3][4] Key Points and Arguments Challenges in Preterm Birth - **Prevalence**: 1 in 10 babies are born prematurely, defined as birth before 37 weeks of gestation [2][3] - **Trends**: Preterm birth rates in the U.S. have increased from 9.4% in 2013 to 10.4% in 2023, indicating a double-digit compound growth rate [5] - **Healthcare Costs**: Prematurity costs the U.S. healthcare system approximately $25 billion annually [4] - **NICU Costs**: Average NICU stay costs around $4,500 per day, with extremely premature babies costing up to $20,000 per day [6] PreTRM Test Overview - **Unique Selling Proposition**: The PreTRM Test is the only clinically validated test for early prediction of premature birth, utilizing proteomics to measure biomarkers [10][15] - **Biomarkers**: The test measures the ratio of IGFBP4 and SHBG proteins to assess risk for spontaneous preterm birth [10][11] - **Timing**: The test is conducted during weeks 18 to 20 of pregnancy, integrating into standard care [11] Clinical Validation and Efficacy - **Clinical Studies**: The PreTRM Test has been validated through studies like AVERT and PRIME, showing significant reductions in NICU admissions and improved neonatal health outcomes [16][19] - **Efficiency**: The number needed to screen to avoid one NICU admission is 40, compared to 150 for traditional methods [17] - **Cost Savings**: Only four women need to be screened to avoid one NICU day stay [20] Commercialization Strategy - **Funding**: Sera Prognostics is well-funded with approximately $110 million in cash and a $30 million annual operating budget [4] - **Targeted States**: The company is focusing on six key states for commercialization, with a sales force and access team to ensure reimbursement and awareness [21][22] - **Partnerships**: Collaborations with payers and digital education channels to increase awareness among clinicians and expectant mothers [23][25] Future Outlook - **Guideline Inclusion**: Aiming for inclusion in clinical guidelines and payer coverage based on clinical evidence [21] - **Health Economic Model**: The breakeven for deploying the test could be achieved within a year, presenting data at the ISPOR Europe Conference [24] - **Community Impact**: The goal is to empower mothers and educate providers to improve health outcomes for babies [25] Additional Important Information - **Healthcare System Impact**: The implications of preterm birth extend beyond immediate healthcare costs, affecting long-term health and economic outcomes for families [6][7] - **Awareness Gap**: Only 20% of expectant mothers are informed about the risks of preterm birth during their first appointment [9] - **Technological Investment**: Sera Prognostics is investing in AI and machine learning to enhance predictive algorithms for the PreTRM Test [13][14] This summary encapsulates the critical insights from the conference call, highlighting the challenges, solutions, and strategic direction of Sera Prognostics in addressing preterm birth risks.

Core Insights - Nautilus Biotechnology, Inc. is participating in multiple investor conferences to enhance visibility and engagement with investors [1][4] Company Overview - Nautilus Biotechnology is a development stage life sciences company headquartered in Seattle, Washington, with R&D operations in San Carlos, California [3] - The company focuses on creating a platform technology for quantifying and analyzing the complexity of the proteome, aiming to democratize access to proteomics and advance human health and medicine [3] Upcoming Events - Management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 10:50 a.m. Pacific Time [4] - A presentation is scheduled for the Q3 Investor Summit Group Virtual Conference on September 16 at 10:00 a.m. Pacific Time, followed by 1x1 meetings on September 17 [4]

REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Seer’s management is scheduled to participate in a fireside chat on Tuesday, September 9th at 12:20 p.m. Eastern Time / 9:20 a.m. Pacific Time. A live webcast of the session will be available on the Investor sectio ...

Summary of Cytek Biosciences (CTKB) Conference Call Industry Overview - The conference focused on advancements in proteomics and cellular research, highlighting the importance of new technologies in these fields [2][3]. Key Companies Discussed - **Cytek Biosciences**: A life science tool company specializing in flow cytometry technology [6]. - **Quantum SI**: A company offering next-generation protein sequencing technology [3]. Core Points and Arguments Technological Advancements - **Quantum SI's Technology**: Introduces next-generation protein sequencing that allows for the study of single amino acid variants and post-translational modifications, which are crucial for understanding disease progression and therapy responses [3][4]. - **Cytek's Full Spectrum Technology**: Enhances flow cytometry by capturing all signals from cells, allowing for the detection of more parameters and improving sensitivity, particularly in cancer studies [6][7][8]. Market Dynamics - **Demand for New Applications**: Both companies noted a shift in customer needs towards more complex studies that traditional technologies could not address [4][5]. - **Challenges in Adoption**: New technologies face skepticism regarding their accuracy and applicability, necessitating proof of concept through data generation in leading research centers [10][11]. Business Management in a Challenging Market - **Financial Resilience**: Quantum SI highlighted its strong balance sheet, allowing it to maintain strategic investments despite market challenges [16][18]. - **Flow Cytometry Market**: Cytek emphasized the ongoing need for flow cytometers in labs, with many existing units nearing replacement, presenting an opportunity for growth [19][20][21]. Replacement Opportunities - **Market Size**: There are approximately 50,000 flow cytometers in use, with many due for replacement, creating a significant market opportunity [22]. - **Key Factors for Replacement**: New technology performance, backward compatibility, and overall cost reduction are critical for capturing replacement opportunities [23][24]. Clinical Market Progress - **Geographic Expansion**: Cytek has received clinical approvals in China and is progressing in Europe, with plans to navigate the more complex FDA approval process in the U.S. [27][28][29]. Future Pipeline and Innovations - **Quantum SI's Proteus Platform**: Expected to launch in 2026, this platform will significantly enhance sequencing capabilities, allowing for more complex sample analysis [36][39]. - **AI Integration**: Both companies are leveraging AI to improve operational efficiency and enhance product capabilities, with Quantum SI focusing on proprietary data to train AI models for better performance [40][41][45]. Additional Important Insights - **Market Disruption**: Cytek views competition as an opportunity to solidify its market leadership, especially in light of disruptions from competitors [25][26]. - **Revenue Growth**: Cytek's revenue growth has outpaced instrument sales, indicating a strong service and reagent business [26]. This summary encapsulates the key discussions and insights from the conference, highlighting the advancements in proteomics and flow cytometry, market dynamics, and future opportunities for both Cytek Biosciences and Quantum SI.

Summary of Quantum-Si (QSI) Conference - August 14, 2025 Industry and Company Overview - **Industry**: Proteomics and Cellular Research - **Companies Involved**: Quantum-Si (QSI) and Cytec Biosciences Key Points and Arguments Quantum-Si's Technology and Applications - Quantum-Si offers next-generation protein sequencing, enabling the reading of individual amino acids, which allows for the study of previously difficult-to-analyze proteins and variants [3][4] - Customers are interested in applications such as single amino acid variants, isomers, and post-translational modifications, which are crucial for understanding therapy responses and disease progression [4] - The U.S. market shows a demand for advanced proteomics tools, while international markets may focus more on basic protein characterization due to limited access [5] Cytec Biosciences' Flow Cytometry Innovations - Cytec specializes in flow cytometry, enhancing conventional technology with full spectrum profiling, which captures more data and improves sensitivity in applications like minimal residual disease (MRD) detection [6][8] - The technology allows for faster drug discovery by enabling the analysis of multiple parameters quickly, addressing the needs of the pharmaceutical industry [9] Market Challenges and Business Management - The academic market is facing challenges, but Quantum-Si maintains a strong balance sheet that allows for strategic investments and operational stability through 2028 [16][17] - Cytec aims to replace older flow cytometers, leveraging the need for advanced features and cost efficiency to capture market opportunities despite tight capital expenditures [19][20] Clinical Market and Regulatory Approvals - Cytec has achieved clinical approvals in China and is progressing in Europe, with tools approved for applications like leukemia and MRD [28][29] - The U.S. FDA approval process is ongoing, which is expected to take longer compared to other regions [30] Future Technology and Market Potential - Quantum-Si is developing a new platform called Proteus, expected to launch in 2026, which will significantly increase sequencing capacity and capabilities [37][40] - The company believes that as technology improves and costs decrease, the adoption of proteomics will mirror the growth seen in DNA sequencing [31][34] Role of AI in Operations and Product Development - Both companies are integrating AI to enhance data analysis and operational efficiency, with Cytec using AI for panel design and Quantum-Si leveraging AI for protein design and analysis [41][42][46] - Quantum-Si has partnered with NVIDIA to improve AI-driven design processes, resulting in significant improvements in amino acid coverage [46][47] Additional Important Insights - The proteomics market is complex, with varying costs and applications, making it difficult to establish a uniform business model [35] - The companies are focused on maintaining their strategic direction and leveraging their technological advancements to capture market share and drive growth [18][21]

Core Insights - Seer, Inc. reported a 32% year-over-year revenue growth, reaching $4.1 million for Q2 2025, driven by increased product sales and service revenue [4][6] - The company launched the high-throughput Proteograph ONE assay and SP200 automation instrument, enhancing scalability and efficiency [3][9] - Seer aims to transform deep, unbiased proteomics, with its technology now supporting multiple population-scale studies [3] Financial Performance - Revenue for Q2 2025 was $4.1 million, up from $3.1 million in Q2 2024, with product revenue at $2.7 million and service revenue at $1.2 million [4][6] - Gross profit was $2.1 million, resulting in a gross margin of 52% for the quarter [5] - Operating expenses decreased by 21% to $22.6 million, primarily due to a reduction in stock-based compensation [5] Net Loss and Cash Position - The net loss for Q2 2025 was $19.4 million, an improvement from a net loss of $22.9 million in the same period last year [6] - As of June 30, 2025, the company had approximately $263.3 million in cash, cash equivalents, and investments [6][9] Future Guidance - Seer expects full-year 2025 revenue to be between $17 million and $18 million, indicating a 24% growth at the midpoint compared to 2024 [7] Recent Developments - The company announced a collaboration with Korea University for a 20,000-sample population-scale proteomics study using the Proteograph ONE assay [9] - Seer has accelerated third-party validation through impactful data presentations and publications from key opinion leaders at recent conferences [9]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $591,000, significantly below expectations, primarily due to a near halt in capital sales of new instruments [7][24] - Gross profit was $351,000, resulting in a gross margin of 59% for the quarter [24] - For the six months ended June 30, 2025, total revenue was $1,400,000, with a gross profit of $837,000 and a gross margin of 58% [25] Business Line Data and Key Metrics Changes - Capital sales of new instruments were the main driver for the revenue decline, while consumable purchases slightly exceeded expectations [7][8] - The installed base of customers is approximately 65% outside the U.S. and 35% within the U.S., encompassing various customer types including academic, industrial, and government research labs [35] Market Data and Key Metrics Changes - The U.S. academic labs experienced a significant slowdown in capital purchases due to NIH funding uncertainties [7][29] - Despite capital market headwinds, consumable purchasing remained consistent across market segments, with government and pharma/biotech accounts showing stable demand [68] Company Strategy and Development Direction - The company aims to accelerate commercial adoption, deliver on its innovation roadmap, and preserve financial strength [6][21] - New instrument acquisition options have been launched to address capital sales headwinds, allowing customers to purchase consumables without upfront capital investment [10][11] - The company remains confident in the long-term market opportunity in proteomics and is focused on growing its installed customer base [11][21] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of NIH funding uncertainties on capital sales and expressed optimism about the potential for growth through new acquisition models [29][30] - The company anticipates that the new models will help capture consumable revenue and improve overall financial performance in the long term [29][70] Other Important Information - The company reported total operating expenses of $30,500,000 for Q2 2025, an increase from $26,800,000 in Q2 2024, while adjusted operating expenses were $23,800,000, slightly down from $24,400,000 [26] - The company ended the quarter with $214,200,000 in cash, cash equivalents, and investments in marketable securities, providing a strong financial position [27][32] Q&A Session Summary Question: How much of the $591,000 revenue is overseas and in pharma/biotech? - The company does not break out revenue by specific segments but noted that 65% of its installed base is outside the U.S. and 35% is within [35] Question: Is $500,000 to $600,000 the bottom for revenue? - Management expressed optimism that this is the bottom and expects gradual improvement, though not instant [36][38] Question: What does a typical placement look like under the new model? - The company offers several models, including capital purchases, reagent rentals, and short-term placements based on consumable revenue potential [40] Question: Are there any trends in leads with the new acquisition opportunities? - Initial data suggests that customers who were previously interested but constrained by capital are now engaging with the new options [46][49] Question: Will Proteus be offered through new models? - Currently, there are no plans to offer Proteus through alternative models; the focus remains on capital sales [61] Question: How is consumable purchasing trending? - Consumable revenue was slightly ahead of expectations, with consistent purchasing across market segments despite capital sales challenges [68] Question: Are the new kits suitable for specific end markets? - The new kits are designed to meet the needs of pharma/biotech customers and are expected to enhance penetration in that segment [72] Question: Is the company considering partnerships or acquisitions given its cash position? - While the company is open to exploring opportunities, the primary focus remains on executing its core technology and business [80][81] Question: If revenue remains soft, where would cuts be made? - The company does not anticipate cuts in the commercial team but will remain targeted in its approach to R&D and operational expenses [85][90]